Physician profile
Danielle Knight
NPI 1578768016
$2,247.00
in general payments reported to CMS, 2019-2025
33 companies · $760 in 2025
The $760 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $64.65 · 2021: $199 · 2022: $138 · 2023: $186 · 2024: $674 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,519.78 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $263.02 | 2023-2025 | |
| Janssen Biotech, INC. | $252.27 | 2022-2025 | Darzalex, Tecvayli, Talvey |
| Clovis Oncology, INC. | $166.08 | 2019 | |
| Seagen INC. | $145.58 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $135.36 | 2023-2025 | |
| Astellas Pharma US INC | $126.18 | 2021-2024 | Padcev |
| Daiichi Sankyo INC. | $108.08 | 2024-2025 | Enhertu, Datroway |
| E.R. Squibb & Sons, L.L.C. | $97.41 | 2019-2025 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $97.24 | 2023-2025 | |
| Genzyme Corporation | $87.74 | 2022-2025 | |
| Lilly USA, LLC | $74.91 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Astrazeneca Pharmaceuticals Lp | $74.76 | 2024-2025 | Lynparza |
| Glaxosmithkline, LLC. | $69.55 | 2024-2025 | Ojjaara, Blenrep |
| Beone Medicines USA, INC. | $49.21 | 2025 | Brukinsa |
| Eisai INC. | $46.08 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $44.16 | 2023-2025 | Trodelvy |
| Genentech USA, INC. | $40.22 | 2019-2024 | Rozlytrek, Tecentriq, Alecensa |
| Stemline Therapeutics INC. | $36.56 | 2023-2024 | Orserdu |
| Caris Mpi, INC. | $35.48 | 2025 | Mi Cancer Seek |
| Geron Corporation | $26.92 | 2024 | Rytelo |
| Deciphera Pharmaceuticals INC. | $25.24 | 2024 | Qinlock, Tgct |
| Next Science LLC | $25.04 | 2023 | Blastx, Xperience, Surgx |
| Merck Sharp & Dohme LLC | $24.88 | 2023 | Keytruda |
| Sobi, INC | $24.41 | 2024 | |
| Genentech, INC. | $23.54 | 2024 | Phesgo, Tecentriq Hybreza |
| Emd Serono, INC. | $22.92 | 2019 | |
| Puma Biotechnology, INC. | $22.38 | 2025 | |
| Alexion Pharmaceuticals, INC. | $19.50 | 2024 | Ultomiris |
| Amgen INC. | $18.36 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $17.45 | 2023 | Tazverik |
| Regeneron Healthcare Solutions, INC. | $16.25 | 2022 | |
| Sumitomo Pharma America, INC. | $15.44 | 2024 | Orgovyx |
| Fortovia Therapeutics, INC. | $14.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Knight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.